Clinical Trials MELD-ATG
ATG, given once in a two days infusion regimen, is a drug recently shown to be able to keep the balance between attacking and regulating cells within the immune system, and thereby helping to preserve insulin secretion.
RECRUITMENT COMPLETED
ATG (Anti Thymocyte Globulin) provided by our partner Sanofi, is a drug tested over 12 months in adolescents to adults (5-25 years of age, n=114). ATG, given once in a two days infusion regimen, recently showed to be able to keep the balance between attacking and regulating cells within the immune system, and thereby helping to preserve insulin secretion. Defining the minimal effective dose of ATG treatment is one aim of the study.
In this movie, the trial specific information starts at minute 3.
Other Innodia Trials:
